NCT05804656View on ClinicalTrials.gov

Efficacy and Safety of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines in Phase 3 Trial

PHASE3CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

April 13, 2023

Primary Completion Date

August 29, 2023

Study Completion Date

November 20, 2023

Conditions
Glabellar Lines
Interventions
DRUG

CKDB-501A

Intramuscular injection CKDB-501A

DRUG

Botox®

Intramuscular injection Botox®

Trial Locations (1)

Unknown

Chung-Ang University Hospital, Seoul

Sponsors
All Listed Sponsors
lead

CKD Bio Corporation

INDUSTRY

NCT05804656 - Efficacy and Safety of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines in Phase 3 Trial | Biotech Hunter | Biotech Hunter